Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.3% – Should You Sell?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) were down 6.3% during mid-day trading on Friday . The stock traded as low as $30.94 and last traded at $31.3110. Approximately 525,588 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 1,315,334 shares. The stock had previously closed at $33.42.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review resumed and a new PDUFA/decision date was set for Deramiocel — a major regulatory catalyst that can materially re‑rate the stock if approval looks likely. Capricor: Moving To ‘Buy’ Rating As New PDUFA Date Is Set For Deramiocel
• Positive Sentiment: Late‑breaking HOPE‑3 Phase 3 data presented at the MDA conference showed significant functional benefits for Deramiocel in DMD, supporting the therapy’s efficacy profile heading into the review. HOPE‑3 Data Release
• Positive Sentiment: Company financial positioning: Capricor highlights roughly $318M cash on hand and frames the FDA milestone as supporting potential commercialization, which reduces near‑term dilution risk. Cash & Commercialization Note
• Positive Sentiment: Analyst support has increased: B. Riley raised its price target to $63 (buy), Piper Sandler reaffirmed overweight and lifted its target to $58, and HC Wainwright reiterated buy — these upgrades boost conviction among buy‑side investors. Benzinga Coverage (B. Riley / Piper Sandler) HC Wainwright Reiterate
• Neutral Sentiment: Management tone is bullish on the regulatory path (CEO pushed back against the idea of only a conditional approval), which supports investor confidence but is not definitive on outcome. CEO Comment
• Negative Sentiment: Q4 results disappointed: EPS of ($0.62) missed consensus (~$0.51) and the loss widened year‑over‑year, prompting intraday selling and headlines calling out the miss. That weakens near‑term sentiment despite the regulatory upside. Q4 Earnings Miss Benzinga: Stock Slides

Wall Street Analyst Weigh In

Several research firms have weighed in on CAPR. B. Riley Financial boosted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday. iA Financial set a $48.00 target price on Capricor Therapeutics in a research report on Wednesday, December 3rd. Maxim Group lifted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Oppenheimer boosted their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Stock Performance

The business has a 50 day moving average of $25.70 and a 200-day moving average of $16.59. The company has a market capitalization of $1.69 billion, a P/E ratio of -13.50 and a beta of 0.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $28,000. Parkside Financial Bank & Trust bought a new position in Capricor Therapeutics in the 3rd quarter valued at $36,000. Russell Investments Group Ltd. grew its position in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at $43,000. Finally, GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $59,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.